ALLEGRIA Therapeutics Secures $5.1M Seed+ Funding to Advance First-in-Class Therapies for Allergic and Mast Cell-Driven Inflammatory Diseases

VCBeat has learned that Allegria Therapeutics (“ALLEGRIA”), a Swiss biotechnology company focused on reshaping the treatment landscape for mast cell-mediated diseases, announced today the successful completion of a $5.1 million Seed+ financing round.

This funding round was led by ALK-Abelló, with participation from HighLight Capital, Lichtsteiner Foundation, and co-founding investor Forty51 Ventures. The proceeds will be used to accelerate the company’s core projects into the preclinical candidate stage and robustly advance its early-stage discovery pipeline, laying a solid foundation for rapid growth and value enhancement.

ALLEGRIA, founded in 2023, has assembled a highly experienced core team and advisory board. The company is dedicated to developing highly differentiated therapeutic strategies and targets, aiming to achieve selective modulation of mast cells. Leveraging its unique scientific insights and R&D strategy, the company has identified multiple molecules with differentiated characteristics, which hold promise as first-in-class and best-in-disease therapies for allergies and related inflammatory diseases.

“ALLEGRIA CEO and Co-Founder Dr. Maria van Dongen stated, ‘We are committed to elucidating the key pathways and targets involved in the aberrant activation of mast cells. Leveraging our team’s extensive expertise in drug development, we aim to provide a broader range of superior therapeutic options for patients suffering from various allergic and inflammatory diseases. This round of financing will provide us with crucial support.’”

Allegria Therapeutics was founded in Basel, Switzerland, by Forty51 Ventures in 2023. The company is dedicated to developing differentiated, innovative therapies that selectively modulate mast cells, aiming to deliver breakthrough treatment options for patients with allergies and mast cell-mediated inflammatory diseases.